多靶点疗法用于狼疮性肾炎维持治疗
本研究为多中心开放标签延长试验,评估多靶点疗法作为狼疮性肾炎维持治疗的效果。116例多靶点组与90例硫唑嘌呤组肾脏复发率相似(5.47% vs 7.62%),但多靶点组不良事件更少(16.4% vs 44.4%),因不良事件退出率更低(1.7% vs 8.9%)。
要点
- 多靶点维持治疗肾脏复发率低,与硫唑嘌呤组无显著差异
- 多靶点组不良事件发生率显著低于硫唑嘌呤组
- 多靶点组因不良事件退出率显著低于硫唑嘌呤组
核心结论
- 多靶点疗法作为狼疮性肾炎维持治疗肾脏复发率低且不良事件更少,是有效且安全的维持治疗方案。
研究设计与样本
- 开放标签、多中心研究,为期18个月,为中国19个肾脏中心诱导治疗试验的延长研究。
- 纳入诱导期24周有应答的患者,多靶点诱导组继续多靶点维持(他克莫司2-3 mg/d、霉酚酸酯0.50-0.75 g/d、泼尼松10 mg/d),环磷酰胺诱导组接受硫唑嘌呤(2 mg/kg/天)加泼尼松10 mg/d。
- 多靶点组116例,硫唑嘌呤组90例。
主要发现
- 多靶点组与硫唑嘌呤组累积肾脏复发率相似(5.47% vs 7.62%;调整风险比0.82;95%CI 0.25-2.67;P=0.74)。
- 两组血清肌酐水平和eGFR保持稳定。
- 硫唑嘌呤组不良事件更多(44.4% vs 16.4%;P<0.01)。
- 多靶点组因不良事件退出率更低(1.7% vs 8.9%;P=0.02)。
临床怎么用
- 对于诱导期有应答的狼疮性肾炎患者,可考虑多靶点疗法作为维持治疗以减少不良事件和退出率。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Our previous studies showed that multitarget therapy is superior in efficacy to intravenous cyclophosphamide as an induction treatment for lupus nephritis in Asian populations. We conducted an open label, multicenter study for 18 months as an extension of the prior induction therapy trial in 19 renal centers in China to assess the efficacy and safety of multitarget maintenance therapy in patients who had responded at 24 weeks during the induction phase. Patients who had undergone multitarget induction therapy continued to receive multitarget therapy (tacrolimus, 2-3 mg/d; mycophenolate mofetil, 0.50-0.75 g/d; prednisone, 10 mg/d), and patients who had received intravenous cyclophosphamide induction treatment received azathioprine (2 mg/kg per day) plus prednisone (10 mg/d). We assessed the renal relapse rate during maintenance therapy as the primary outcome. We recruited 116 patients in the multitarget group and 90 patients in the azathioprine group. The multitarget and azathioprine groups had similar cumulative renal relapse rates (5.47% versus 7.62%, respectively; adjusted hazard ratio, 0.82; 95% confidence interval, 0.25 to 2.67; P=0.74), and serum creatinine levels and eGFR remained stable in both groups. The azathioprine group had more adverse events (44.4% versus 16.4% for multitarget therapy; P<0.01), and the multitarget group had a lower withdrawal rate due to adverse events (1.7% versus 8.9% for azathioprine; P=0.02). In conclusion, multitarget therapy as a maintenance treatment for lupus nephritis resulted in a low renal relapse rate and fewer adverse events, suggesting that multitarget therapy is an effective and safe maintenance treatment for patients with lupus nephritis.
引用
- Zhang H, Liu Z, Zhou M, et al. Multitarget Therapy for Maintenance Treatment of Lupus Nephritis. J Am Soc Nephrol. 2017. PMID: 28760751. doi:10.1681/ASN.2017030263
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。